The combination trimethoprim-sulfamethoxazole had no greater activity in a murine model of toxoplasmosis than did sulfamethoxazole alone.
Preparation and administration of trimethoprim and sulfamethoxazole. Trimethoprim (lot no. 56538) and sulfamethoxazole (lot no. 734094) were supplied in the powder form by E. Grunberg, Hoffmann-La Roche, Inc., Nutley, N.J. The amount of drug in the diet was given in milligram amounts per 4 g of food since mice consumed approximately 4 g of the diet each day (3) . The drugs were mixed individually or together with the powdered form of normal mouse chow (S/L maintenance diet, Simonsen Laboratories, Inc., Gilroy, Calif.). Initial experiments, performed to determine the palatability of the drugchow mixtures, revealed that, over a period of 14 days, uninfected mice consumed essentially the same amount of each of the drug-chow diets as they did of the diet without drug. The drug-chow diet was begun immediately after infection and continued for 14 days.
Toxoplasma inoculum. Mice were inoculated intraperitoneally with 0.2 ml of saline containing 5 x 104 trophozoites of the RH strain harvested from the peritoneal fluid of infected mice, as previously described (5) . Control mice were inoculated with saline alone. Animals were followed for time to death. In two experiments, portions of liver, spleen, and brain of survivors were inoculated intraperitoneally into normal mice to test for residual infection.
RESULTS
Five separate experiments were performed. In each experiment there were 10 mice per group. The results were essentially the same in each. In Table 1 are representative results obtained in one of the experiments. As previously found (8) , trimethoprim had no demonstrable activity in the doses used. Sulfamethoxaole, however, was active; in three experiments, the mortality at 156 mg/kg was 0, 30, and 90%. In all experiments, 312 mg/kg resulted in 100% survival and 78 mg/kg resulted in 100% mortality. The organs of mice treated with 625 mg/kg were essentially free from T. gondii, as mice inoculated with their organs did not (lie of the infection (less than 10 organisms of the RH strain will cause death in 100% of inoculated mice). No synergistic effect was noted when trimethoprim (250 mg/kg) was added to the sulfamethoxazole.
DISCUSSION
The results obtained in this study did not reveal any synergistic effect of trimethoprim and sulfamethoxazole against murine toxoplasmosis. In the one other study in which the effectiveness of sulfamethoxazole alone and in combination with trimethoprim was examined, Sander and Midtvedt (9) found that trimethoprim had a significant sulfonamide potentiating effect in experimental toxoplasmosis in mice. After 20 days of treatment, survival was greater (p < 0.005) in mice receiving trimethoprim (100 mg/kg) plus sulfamethoxazole alone (50 mg/kg). However, mortality, after the 20 days of treatment was concluded, was higher in the groups that received both drugs (59%) than in those treated with the sulfonamide alone (20%).
The lack of effectiveness of trimethoprim alone when compared with the remarkable effectiveness of pyrimethamine and the absence of demonstrated efficacy of the former drug when combined with sulfamethoxazole (the combination presently marketed worldwide) suggest that the combination trimethoprim-sulfamethoxazole should not be depended upon in cases of human toxoplasmosis.
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